Investing.com -- AirSculpt Technologies, a provider of aesthetic body-contouring procedures, saw its shares fall by 32% in premarket trading after it reported preliminary 2024 results that fell short of the company's guidance and analyst estimates.
The company's preliminary revenue for 2024 is reported at $180 million, which is lower than the forecast range of $183 million to $189 million. The average analyst estimate for the period was $185.4 million.
Additionally, the 2024 adjusted Ebitda (Earnings before interest, tax, depreciation, and amortization) is projected at $20.5 million. This is less than AIRS's own projection of $23 million to $28 million and the analyst estimate of $24.2 million.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Is AIRS truely undervalued?
With AIRS making headlines, investors are asking: Is it truly valued fairly? InvestingPro's advanced AI algorithms have analyzed AIRS alongside thousands of other stocks to uncover hidden gems with massive upside. And guess what? AIRS wasn't at the top of the list.
Unlock ProPicks AI